Gilead Sciences, Inc.

Joshua J Van Veldhuizen

Gary Bruce Phillips

Jennifer Alissa Loyer-Drew

Suet Chung Yeung

Musong Kim

Julian Andrew Codelli

Jennifer Anne Treiberg

Devan Naduthambi

Jayaraman Chandrasekhar

Stephane Perreault

Mark J Bartlett

Jeff A Zablocki

William John Watkins

Scott A Mitchell

Rao V Kalla

Thao Perry

Seung H Lee

Eda Y Canales

Leena Patel

Jennifer R Lo

Gayatri Balan

John H Conway

Jennifer Leigh Cosman

Patrick J Salvo

James G Taylor

Hyung-Jung Pyun

Barton W Phillips

Sundaramoorthi Swaminathan

Petr Jansa

Joshua A Kaplan

Adam James Schrier

Zhimin Du

Michael Sangi

Roland D Saito

Marina Shatskikh

Weng K Chang

Zachary A Kasun

Laurent P Debien

Lianhong Xu

Scott D Schroeder

Rick Andrew Lee

Jerry B Evarts

Michael R Mish

Kirk L Stevens

Gregory F Chin

Stephen E Ammann

Daniel H Byun

Jason K Perry

Kassandra F Sedillo

Shaopei Cai

Henok H Kinfe

Christopher J Swank

Jessica L McKinley

Xinpei Cai

Kevin X Rodriguez

Scott E Lazerwith

Michael L Mitchell

Richard Y Huang

Britton Kenneth Corkey

Ryan McFadden

David Sperandio

Hai Yang

Zhenhong R Cai

Kristyna M Elbel

Jennifer L Cosman Ellis

Nicholas Alexander Till

Luisruben P Martinez

Timothy R Hansen

Thao D Perry

William J Watxins

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted 6-azabenzimidazole compounds

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

SARS-COV2 main protease inhibitors

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R, R, R, R, and Rare as described herein.

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W, W, W, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

The present application provides the compounds of formula I or IA 

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Growing community of inventors

Seattle, WA, United States of America

Joshua J Van Veldhuizen